AstraZeneca PLC Filing of Form 20-F with SEC (6062Q)
February 22 2023 - 2:10AM
UK Regulatory
TIDMAZN
RNS Number : 6062Q
AstraZeneca PLC
22 February 2023
22 February 2023 07:10 GMT
Filing of Annual Report on Form 20-F with the US Securities and
Exchange Commission
AstraZeneca PLC (the Company) announced today that, on 21
February 2023, it filed its 2022 Annual Report on Form 20-F with
the US Securities and Exchange Commission (SEC). The document is
available for viewing on the SEC website at www.sec.gov and also on
the Company's website at www.astrazeneca.com . The Company will
send any holder of the Company's securities, upon request, a hard
copy of the Company's complete audited financial statements free of
charge. Requests may be made by writing to the Company Secretary,
AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical
Campus, Cambridge, CB2 0AA, UK.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEIFDFEDSEDE
(END) Dow Jones Newswires
February 22, 2023 02:10 ET (07:10 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024